Journal of Psychoactive Drugs, 47(2), 125131
2016 Jan 19;5:193-7
Thankfully, a few months after my own experience, which was January 2024, where I'm getting these emails, thankfully, ultimately the Washington Post covered the story and broke it wide open
These results highlight a total transformation, addressing not only physical metrics but also the crucial psychological and behavioral aspects of a healthy relationship with food
In August 2025 it received accelerated FDA approval for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis, becoming the first GLP-1 receptor agonist approved for MASH, alongside resmetirom as the only approved therapies for this indication, on the basis of the Phase 3 ESSENCE trial in which resolution of steatohepatitis without worsening of fibrosis was achieved in 63% of patients on semaglutide versus 34% on placebo at week 72
Doctors say it is far too early to know whether it can clear those hurdles
